Predicted Heart Rate Effect of Inhaled PF-00610355, a Long Acting β-adrenoceptor Agonist, in Volunteers and Patients with Chronic Obstructive Pulmonary Disease

Overview

Journal Br J Clin Pharmacol

Specialty Pharmacology

Date 2013 Jan 18

PMID 23323609

Citations 3

Authors

Paul Matthias Diderichsen

Eugene Cox

Steven W Martin

Adriaan Cleton

Jakob Ribbing

Affiliations

Soon will be listed here.

Abstract

Aim: To assess the cardiovascular effects of a new inhaled long-acting β-adrenoceptor agonist PF-00610355 in COPD patients.

Methods: Thirteen thousand and sixty-two heart rate measurements collected in 10 clinical studies from 579 healthy volunteers, asthma and COPD patients were analyzed. The relationship between heart rate profiles and predicted plasma concentration profiles, patient status, demographics and concomitant medication was evaluated using non-linear mixed-effects models. The median heart rate increase in COPD patients for doses of PF-00610355 up to 280 μg once daily was simulated with the final pharmacokinetic/pharmacodynamic (PKPD) model.

Results: An Emax model accounting for delayed on-and off-set of the PF-00610355-induced change in heart rate was developed. The predicted potency in COPD patients was three-fold lower compared with healthy volunteers, while no difference in maximum drug effect was identified. Simulations suggested a maximum placebo-corrected increase of 2.7 (0.90-4.82) beats min(-1) in COPD patients for a PF-00610355 dose of 280 μg once daily, with 19% subjects experiencing a heart rate increase of more than 20 beats min(-1) compared with 8% in the placebo group.

Conclusions: This PKPD analysis supports the clinical observation that no relevant effects of PF-00610355 on heart rate in COPD patients should be expected for doses up to 280 μg once daily.

Citing Articles

Ultra Long-Acting β-Agonists in Chronic Obstructive Pulmonary Disease.

Burkes R, Panos R J Exp Pharmacol. 2020; 12:589-602.

PMID: 33364854 PMC: 7751789. DOI: 10.2147/JEP.S259328.

Toward a Taxonomy for Analyzing the Heart Rate as a Physiological Indicator of Posttraumatic Stress Disorder: Systematic Review and Development of a Framework.

Sadeghi M, Sasangohar F, McDonald A JMIR Ment Health. 2020; 7(7):e16654.

PMID: 32706710 PMC: 7407264. DOI: 10.2196/16654.

Characterizing systemic exposure of inhaled drugs: application to the long-acting β2-agonist PF-00610355.

Diderichsen P, Cox E, Martin S, Cleton A, Ribbing J Clin Pharmacokinet. 2013; 52(6):443-52.

PMID: 23494982 DOI: 10.1007/s40262-013-0048-7.

References

Rossi A, Kristufek P, Levine B, Thomson M, Till D, Kottakis J . Comparison of the efficacy, tolerability, and safety of formoterol dry powder and oral, slow-release theophylline in the treatment of COPD. Chest. 2002; 121(4):1058-69. DOI: 10.1378/chest.121.4.1058. View

Lindbom L, Pihlgren P, Jonsson E, Jonsson N . PsN-Toolkit--a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. Comput Methods Programs Biomed. 2005; 79(3):241-57. DOI: 10.1016/j.cmpb.2005.04.005. View

Feldman G, Siler T, Prasad N, Jack D, Piggott S, Owen R . Efficacy and safety of indacaterol 150 microg once-daily in COPD: a double-blind, randomised, 12-week study. BMC Pulm Med. 2010; 10:11. PMC: 2848004. DOI: 10.1186/1471-2466-10-11. View

Diderichsen P, Cox E, Martin S, Cleton A, Ribbing J . Characterizing systemic exposure of inhaled drugs: application to the long-acting β2-agonist PF-00610355. Clin Pharmacokinet. 2013; 52(6):443-52. DOI: 10.1007/s40262-013-0048-7. View

Paul L, Hastie C, Li W, Harrow C, Muir S, Connell J . Resting heart rate pattern during follow-up and mortality in hypertensive patients. Hypertension. 2009; 55(2):567-74. DOI: 10.1161/HYPERTENSIONAHA.109.144808. View

Sheiner L, Stanski D, Vozeh S, Miller R, Ham J . Simultaneous modeling of pharmacokinetics and pharmacodynamics: application to d-tubocurarine. Clin Pharmacol Ther. 1979; 25(3):358-71. DOI: 10.1002/cpt1979253358. View

Bergstrand M, Hooker A, Wallin J, Karlsson M . Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J. 2011; 13(2):143-51. PMC: 3085712. DOI: 10.1208/s12248-011-9255-z. View

Sin D, Paul Man S . Corticosteroids and adrenoceptor agonists: the compliments for combination therapy in chronic airways diseases. Eur J Pharmacol. 2006; 533(1-3):28-35. DOI: 10.1016/j.ejphar.2005.12.049. View

Dansirikul C, Silber H, Karlsson M . Approaches to handling pharmacodynamic baseline responses. J Pharmacokinet Pharmacodyn. 2008; 35(3):269-83. DOI: 10.1007/s10928-008-9088-2. View

10.

Stewart A, Waterhouse J, Howard P . The QTc interval, autonomic neuropathy and mortality in hypoxaemic COPD. Respir Med. 1995; 89(2):79-84. DOI: 10.1016/0954-6111(95)90188-4. View

11.

Singh S, Loke Y, Furberg C . Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA. 2008; 300(12):1439-50. DOI: 10.1001/jama.300.12.1439. View

12.

Cazzola M, Imperatore F, Salzillo A, Di Perna F, Calderaro F, Imperatore A . Cardiac effects of formoterol and salmeterol in patients suffering from COPD with preexisting cardiac arrhythmias and hypoxemia. Chest. 1998; 114(2):411-5. DOI: 10.1378/chest.114.2.411. View

13.

Porchet H, Benowitz N, Sheiner L . Pharmacodynamic model of tolerance: application to nicotine. J Pharmacol Exp Ther. 1988; 244(1):231-6. View

14.

Bhagat R, Kalra S, Swystun V, Cockcroft D . Rapid onset of tolerance to the bronchoprotective effect of salmeterol. Chest. 1995; 108(5):1235-9. DOI: 10.1378/chest.108.5.1235. View

15.

Decramer M, Ferguson G . Clinical safety of long-acting beta2-agonist and inhaled corticosteroid combination therapy in COPD. COPD. 2007; 3(3):163-71. DOI: 10.1080/15412550600830263. View

16.

Boyd G, Morice A, Pounsford J, Siebert M, Peslis N, Crawford C . An evaluation of salmeterol in the treatment of chronic obstructive pulmonary disease (COPD). Eur Respir J. 1997; 10(4):815-21. View

17.

Celli B, Decramer M, Leimer I, Vogel U, Kesten S, Tashkin D . Cardiovascular safety of tiotropium in patients with COPD. Chest. 2009; 137(1):20-30. DOI: 10.1378/chest.09-0011. View

18.

Nielsen J, Hutmacher M, Cleton A, Martin S, Ribbing J . Longitudinal FEV1 dose-response model for inhaled PF-00610355 and salmeterol in patients with chronic obstructive pulmonary disease. J Pharmacokinet Pharmacodyn. 2012; 39(6):619-34. DOI: 10.1007/s10928-012-9274-0. View

19.

Van de Maele B, Fabbri L, Martin C, Horton R, Dolker M, Overend T . Cardiovascular safety of QVA149, a combination of Indacaterol and NVA237, in COPD patients. COPD. 2010; 7(6):418-27. DOI: 10.3109/15412555.2010.528812. View

20.

Glossop P, Lane C, Price D, Bunnage M, Lewthwaite R, James K . Inhalation by design: novel ultra-long-acting β(2)-adrenoreceptor agonists for inhaled once-daily treatment of asthma and chronic obstructive pulmonary disease that utilize a sulfonamide agonist headgroup. J Med Chem. 2010; 53(18):6640-52. DOI: 10.1021/jm1005989. View